

1


2 **Supplementary Figure 1.**

3 The representative blot from Figure 1i is shown, uncropped, with molecular weight
4 markers.

5 Figure Legend 1i: mGluR1 coimmunoprecipitates with βarr2 in wild type cortex (Cx),
6 hippocampus (Hp), and cerebellum (Cb), but not with an IgG isotype control antibody
7 (n=3 replicated observations by Western blotting). Positive βarr2 immunoreactivity was
8 observed in immunoprecipitation (IP) and lysate preparations loaded into the same gel.

9 Blotting for βarr2 in the rabbit anti-IgG antibody resulted in strong signal ~50-51 kDa
10 during short exposures, consistent with detection of the rabbit IgG heavy chain by the
11 goat anti-rabbit secondary antibody.

12




13

14 **Supplementary Figure 2.**

15 mGluR1 coimmunoprecipitates with β arr2 in wild type cortex (Cx), hippocampus (Hp),
 16 and cerebellum (Cb) in wild type, but not mGluR1^{-/-} brain tissue preparations.(n=3
 17 blots). β arr2 expression was verified in the β arr2 immunoprecipitation and input
 18 preparations loaded into the same gel.

19




20

21 **Supplementary Figure 3.**

22 The representative blot from Figure 6h is shown, uncropped, with molecular weight
 23 markers.

24 Figure Legend 6h: Monomeric mGluR5 (yellow arrow) and GluK2 immunoreactivity was
 25 detected in both the $\betaarr2^{+/+}$ and $\betaarr2^{-/-}$ surface biotinylated fractions by Western
 26 blotting, and less so in the non-biotinylated fractions (n=3 pairs of $\betaarr2^{+/+}$ and $\betaarr2^{-/-}$
 27 mice). β -tubulin immunoreactivity indicated that intracellular proteins were enriched in
 28 the non-biotinylated fraction. Quantitated monomeric mGluR5 optical density normalized
 29 against the GluK2 signal is provided in a bar graph illustrating the mean and SEM.




30

31 **Supplementary Figure 4.**

32 (a) Representative mGluR5 and actin immunoblotting results from wild type and β arr2-
 33 null tissue are provided. The blotting membrane containing proteins from the same gel
 34 was cut near the 75 kDa marker. The portion of membrane containing proteins 75 kDa
 35 or greater was immunoblotted for mGluR5 (~150 kDa, n=2 replicated observations) and
 36 robust immunoreactivity was detected in the total and membrane-enriched fractions. In
 37 contrast, actin expression was enriched in the cytosolic-enriched fraction relative to the
 38 other lysate preparation conditions.

39 (b-c) Total and cytosolic levels of mGluR5 protein measured as actin-normalized optical
 40 density, was unaltered in β arr2^{-/-} brain tissue compared to wild type (0.85 ± 0.13 a.u. for
 41 β arr2^{+/+} total fraction normalized to actin, 1.0 ± 0.28 a.u. for β arr2^{-/-} total fraction
 42 normalized to actin, and 0.12 ± 0.08 for wild type cytosolic fraction normalized to actin,
 43 0.13 ± 0.08 for β arr2^{-/-} cytosolic fraction normalized to actin n=2). The percentage of
 44 membrane-bound mGluR5 was similar in wild type and β arr2^{-/-} brain tissue (89 ± 6% for
 45 wild type, 89 ± 5% for β arr2^{-/-}, p=0.95, n=2; Mann-Whitney test).




46

47 **Supplementary Figure 5.**

48 The representative blot from Figure 6i is shown, uncropped, with molecular weight
 49 markers.

50 Figure Legend 6i: mGluR5 receptors co-immunoprecipitate with β-arrestin2 in the cortex
 51 and hippocampus of wild type mouse brains (n=5 blots). Pull-down by an IgG isotype
 52 antibody yields little mGlu5 receptor immunoreactivity. Robust β -arrestin2 is strongly
 53 detected in the immunoprecipitation and input conditions.

54




55

56 **Supplementary Figure 6.**

57 mGlu5 receptors coimmunoprecipitate with β arr2 protein in wild type cortex (Cx),
58 hippocampus (Hp), and cerebellum (Cb), whereas mGluR5 immunoreactivity is not
59 observed in mGluR5^{-/-} mouse brain tissue (n=3 blots). Expression of β arr2 was
60 confirmed in the immunoprecipitation and input protein samples loaded into the same
61 gel.

62



63

64 **Supplementary Figure 7.**

65 (a-c) Putative arrestin-biased agonist succinate (1 mM) has no effect on plasticity

66 induced by PP-LFS. Post-train amplitudes were $163 \pm 28\%$ for vehicle “BPA” treated

67 cells, $n=6$ cells and $150 \pm 14\%$ for succinate treated cells, $n=8$ cells ($p=0.95$, Mann-

68 Whitney test). A cumulative probability histogram and box plot summarize the post-train


69 data.

70 (d-f) Succinate provided in the presence of the mGluR5 antagonist MTEP has no effect

71 on basal mf-CA3 synaptic transmission. Post-application amplitudes were $89 \pm 12\%$ for

72 the vehicle “BPA+MTEP” condition, n=4 cells and $82 \pm 15\%$ for the succinate+MTEP
73 condition, n=6 cells ($p=0.61$, Mann-Whitney test). A cumulative probability histogram
74 and 10-90% box plot summarize the population data for post-train mfEPSC amplitudes.
75 Calibration of representative traces: x-axes, 10 ms; y-axes, 250 pA.

76



77

78 **Supplementary Figure 8.**

79 (a) A representative immunoblot of pERK1/2 and ERK1/2 from the same gel and wild
 80 type mouse brain are shown. Acute brain slices from the animal were pre-treated for 15
 81 min with u0126 (20 μ M, “PDBu + u0126”) or GW5074 (1 μ M, “PDBu + GW5074”) prior
 82 to incubation in phorbol 12,13 butyrate for 15 min (PDBu, 1 μ M). Control “No PDBu” and
 83 PDBu-only conditions show basal and maximal pERK signal under these experimental
 84 conditions.

85 (b) Quantitative densitometry analysis of the five independent PDBu experiment
 86 replicates illustrates the significant reduction of PDBu-induced pERK upregulation by
 87 u0126 and GW5074 compared to treatment with PDBu alone. Phosphorylation of
 88 ERK1/2 in the “No PDBu” condition is significantly less than that induced by incubation
 89 in PDBu. Quantitated optical densities as a percentage of the PDBu-stimulated pERK
 90 immunoreactivity were as follows: 20 \pm 5% for PDBu alone, 1.0 \pm 0.6% for u0126, and
 91 65 \pm 10% for GW5074; the results were compared by One-way ANOVA and post-hoc
 92 Tukey multiple comparison tests.

93 Asterisks denote significant differences between treatment groups (** $p < 0.01$, *** $p <$
94 0.001).